Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Heidegger

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral responseCarole Bourquin, Cornelia Wurzenberger, Simon Heidegger, et al.
Oncoimmunology|March 26, 2019
Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccinesSarah Bek, Florian Stritzke, Alexander Wintges, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 2015
TLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral InfectionChristian Hotz, Laurin C Roetzer, Thomas Huber, et al.
Scientific Reports|October 20, 2019
Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cellsJulius C Fischer, Michael Bscheider, Sascha Göttert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 21, 2021
Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case ReportRebecca Wicklein, Simon Heidegger, Mareike Verbeek, et al.
Cancer Research|June 24, 2011
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR toleranceCarole Bourquin, Christian Hotz, Daniel Noerenberg, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 8, 2025
Expression of vesiculation-related genes is associated with a tumor-promoting microenvironment: a pan-cancer analysisLuisa Westermann, Brenda Diergaarde, Simon Heidegger, et al.
Cancer Research|April 30, 2025
Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T Cell Therapy in Solid TumorsNardine Soliman, Tatiana Nedelko, Giada Mandracci, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2013
TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in miceSimon Heidegger, Sophie-Kathrin Kirchner, Nicolas Stephan, et al.
International Journal of Radiation Oncology, Biology, Physics|December 4, 2018
Regeneration After Radiation- and Immune-Mediated Tissue Injury Is Not Enhanced by Type III Interferon SignalingJulius C Fischer, Chia-Ching Lin, Simon Heidegger, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral responseCarole Bourquin, Cornelia Wurzenberger, Simon Heidegger, et al.
Oncoimmunology|March 26, 2019
Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccinesSarah Bek, Florian Stritzke, Alexander Wintges, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 2015
TLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral InfectionChristian Hotz, Laurin C Roetzer, Thomas Huber, et al.
Scientific Reports|October 20, 2019
Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cellsJulius C Fischer, Michael Bscheider, Sascha Göttert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 21, 2021
Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case ReportRebecca Wicklein, Simon Heidegger, Mareike Verbeek, et al.
Cancer Research|June 24, 2011
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR toleranceCarole Bourquin, Christian Hotz, Daniel Noerenberg, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 8, 2025
Expression of vesiculation-related genes is associated with a tumor-promoting microenvironment: a pan-cancer analysisLuisa Westermann, Brenda Diergaarde, Simon Heidegger, et al.
Cancer Research|April 30, 2025
Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T Cell Therapy in Solid TumorsNardine Soliman, Tatiana Nedelko, Giada Mandracci, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2013
TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in miceSimon Heidegger, Sophie-Kathrin Kirchner, Nicolas Stephan, et al.
International Journal of Radiation Oncology, Biology, Physics|December 4, 2018
Regeneration After Radiation- and Immune-Mediated Tissue Injury Is Not Enhanced by Type III Interferon SignalingJulius C Fischer, Chia-Ching Lin, Simon Heidegger, et al.
Pageof 4